AptaBio Therapeutics Inc.
Financials
Valuation Metrics
AptaBio Therapeutics Inc.'s Market Cap is ₩1711B. At end of 2025 it was ₩2627B. Ranked #947 of 2,421 in KR market (top 39%), #459 of 1,640 on KOSDAQ (top 28%), #106 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 46%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 171.09B KRW | KR#947/2,421 Sec#106/231 |
| Revenue | 4.75B KRW | KR#2,345/2,421 Sec#198/231 |
| Net Income | -14.87B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 54.40B KRW | KR#2,168/2,421 Sec#193/231 |
| Net Assets | 42.20B KRW | KR#2,017/2,421 Sec#175/231 |
| Employees | 34 | KR#2,178/2,421 Sec#201/231 |
| Value | ||
| P/B | 4.05x | KR#2,195/2,421 Sec#180/231 |
| P/S | 35.99x | KR#2,365/2,421 Sec#194/231 |
| Profitability | ||
| ROE | -35.23% | KR#2,221/2,421 Sec#188/231 |
| ROA | -27.34% | KR#2,301/2,421 Sec#195/231 |
| Op. Margin | -394.38% | KR#2,359/2,421 Sec#199/231 |
| Revenue Growth | 52.91% | KR#190/2,421 Sec#25/231 |
| Financial Health | ||
| Debt Ratio | 28.90% | KR#557/2,421 Sec#63/231 |
| Total Debt | 11.98B KRW | KR#1,567/2,421 Sec#138/231 |
| Cash | 14.71B KRW | KR#1,444/2,421 Sec#116/231 |
| Current Ratio | 2.54x | KR#676/2,421 Sec#85/231 |
| Performance | ||
| 1Y Return | -26.36% | KR#1,446/2,421 Sec#107/231 |
| 1M Return | -1.77% | KR#1,453/2,421 Sec#111/231 |
| From 52W High | -44.08% | KR#1,115/2,421 Sec#85/231 |
| 1Y MDD | -61.61% | KR#1,571/2,421 Sec#126/231 |
| Trading | ||
| Volume | 84,576 shares | KR#864/2,421 Sec#83/231 |
| Trading Value | 509.0M KRW | KR#916/2,421 Sec#93/231 |
| Foreign Own. | 1.45% | KR#1,845/2,421 Sec#181/231 |
| Per Share | ||
| EPS | -529 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,502 KRW | KR#2,194/2,421 Sec#190/231 |
Company Info
Aptabio, established in 2009 and specially listed on KOSDAQ in 2019, is a new drug development company based on platform technology, headquartered in Yongin-si, Gyeonggi-do. The company develops innovative new drugs, including for diabetes complications and as immune-oncology agents, utilizing three platform technologies: oxidative stress regulation, CAF modulation, and aptamer-drug conjugates. Aptabio launched health functional food Original Design Manufacturer (ODM) and pet care businesses in 2023, plans to merge Objectivo in 2025, and has successfully achieved three technology transfers with its proprietary technologies.